ADMA Biologics, Inc. (ADMA)
| Market Cap | 2.31B -50.6% |
| Revenue (ttm) | 510.17M +19.6% |
| Net Income | 146.93M -25.7% |
| EPS | 0.60 -25.9% |
| Shares Out | 238.16M |
| PE Ratio | 16.17 |
| Forward PE | 10.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,878,805 |
| Open | 9.88 |
| Previous Close | 9.94 |
| Day's Range | 9.66 - 10.03 |
| 52-Week Range | 7.21 - 25.67 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 32.00 (+229.9%) |
| Earnings Date | May 6, 2026 |
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal anti... [Read more]
Financial Performance
In 2025, ADMA Biologics's revenue was $510.17 million, an increase of 19.63% compared to the previous year's $426.45 million. Earnings were $146.93 million, a decrease of -25.67%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ADMA stock is "Buy." The 12-month stock price target is $32.0, which is an increase of 229.90% from the latest price.
News
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. , a top complex litigation law firm, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential...
ADMA Fraud Notice: ADMA Biologics Investors are Notified the Company is being Investigated for Securities Fraud after 29% Stock Drop — BFA Law
NEW YORK--(BUSINESS WIRE)---- $ADMA #ADMA--ADMA Biologics Investors are Notified the Company is being Investigated for Securities Fraud after 29% Stock Drop.
Bragar Eagel & Squire, P.C. Urges ADMA Biologics, Inc. (NASDAQ:ADMA) Investors to Contact the Firm Regarding Ongoing Investigation
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ADMA To Contact Him Directly To Discuss Their Options
ADMA Investor Announcement: ADMA Biologics Investigated After Channel Stuffing Claims Cause 29% Stock Drop – Investors with Losses Notified to Contact BFA Law
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the ...
Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation – Investors Urged to Contact BFA Law
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the f...
$ADMA Stock News: ADMA Biologics Investigated for Securities Fraud Following Channel Stuffing Claims – Investors Notified to Contact BFA Law
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the ...
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
SAN FRANCISCO, April 01, 2026 (GLOBE NEWSWIRE) -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's repo...
ADMA Securities News: ADMA Biologics Investigated for Securities Fraud After Culper Research Report Revelation Sparks 29% Stock Drop
BFA Law is investigating ADMA Biologics after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws. NEW YORK, March 31, 2026 /PRNewswir...
$ADMA Investor News: ADMA Biologics Faces Securities Fraud Investigation after Culper Research Revelation Leads to 29% Stock Drop – BFA Law Notifies Investors to Act
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the f...
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and The...
$ADMA Shareholders: ADMA Biologics Hit with Securities Fraud Investigation After Stock Slides 29% Amid Channel Stuffing Claims – Investors with Losses Alerted to Contact BFA Law
ADMA Biologics Hit with Securities Fraud Investigation After Stock Slides 29% Amid Channel Stuffing Claims – Investors with Losses Alerted to Contact BFA
ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $ADMA #ADMA--BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law.
Short Seller Report Alleges ADMA Biologics Financial Misrepresentation
• ADMA Biologics stock is testing key support levels. What's pressuring ADMA?
ADMA Biologics Addresses Misleading Short-Seller Report
RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedic...
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income( 1) of $1...
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA(1) and Adjusted Net Income(2) Guidance Reitera...
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedica...
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase 3Q 2025 Adjust...
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue ( 1) of $118.6 Million), a 40% YoY Increase
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
RAMSEY, N.J. and BOCA RATON, Fla.